

Nikolaos Nikolaou

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6601722/publications.pdf>

Version: 2024-02-01

20
papers

431
citations

1039880

9
h-index

996849

15
g-index

22
all docs

22
docs citations

22
times ranked

881
citing authors

#	ARTICLE	IF	CITATIONS
1	Development of Hepatocellular Carcinoma in a Murine Model of Nonalcoholic Steatohepatitis Induced by Use of a High-Fat/Fructose Diet and Sedentary Lifestyle. <i>American Journal of Pathology</i> , 2014, 184, 1550-1561.	1.9	91
2	Loss of 5 α -Reductase Type 1 Accelerates the Development of Hepatic Steatosis but Protects Against Hepatocellular Carcinoma in Male Mice. <i>Endocrinology</i> , 2013, 154, 4536-4547.	1.4	67
3	AKR1D1 is a novel regulator of metabolic phenotype in human hepatocytes and is dysregulated in non-alcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , 2019, 99, 67-80.	1.5	52
4	Dual-5 α -Reductase Inhibition Promotes Hepatic Lipid Accumulation in Man. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 103-113.	1.8	50
5	5 α -Reductase Type 2 Regulates Glucocorticoid Action and Metabolic Phenotype in Human Hepatocytes. <i>Endocrinology</i> , 2015, 156, 2863-2871.	1.4	38
6	Modified release and conventional glucocorticoids and diurnal androgen excretion in congenital adrenal hyperplasia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, jc.2016-2855.	1.8	38
7	Optimizing human hepatocyte models for metabolic phenotype and function: effects of treatment with dimethyl sulfoxide (DMSO). <i>Physiological Reports</i> , 2016, 4, e12944.	0.7	21
8	AKR1D1 regulates glucocorticoid availability and glucocorticoid receptor activation in human hepatoma cells. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2019, 189, 218-227.	1.2	16
9	The A-ring reduction of 11-ketotestosterone is efficiently catalysed by AKR1D1 and SRD5A2 but not SRD5A1. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2020, 202, 105724.	1.2	13
10	Co-administration of 5 α -reductase Inhibitors Worsens the Adverse Metabolic Effects of Prescribed Glucocorticoids. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e3316-e3328.	1.8	9
11	The role of 5-reduction in physiology and metabolic disease: evidence from cellular, pre-clinical and human studies. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2021, 207, 105808.	1.2	9
12	Glucocorticoids regulate AKR1D1 activity in human liver in vitro and in vivo. <i>Journal of Endocrinology</i> , 2020, 245, 207-218.	1.2	9
13	AKR1D1 knockout mice develop a sex-dependent metabolic phenotype. <i>Journal of Endocrinology</i> , 2022, 253, 97-113.	1.2	7
14	Acute intermittent hypoxia drives hepatic de novo lipogenesis in humans and rodents. <i>Metabolism Open</i> , 2022, 14, 100177.	1.4	6
15	Differential activity and expression of human 5 α -reductase (AKR1D1) splice variants. <i>Journal of Molecular Endocrinology</i> , 2021, 66, 181-194.	1.1	3
16	Gender specific metabolic phenotype in the 5[beta]-reductase knockout mouse. <i>Endocrine Abstracts</i> , 0, , .	0.0	1
17	Androgen receptor over expression drives lipid accumulation in human hepatocytes. <i>Endocrine Abstracts</i> , 0, , .	0.0	0
18	Model systems to define the role of AKR1D1 in metabolic liver disease. <i>Endocrine Abstracts</i> , 0, , .	0.0	0

#	ARTICLE	IF	CITATIONS
19	5[beta]-reductase (AKR1D1) is a potent regulator of hepatic insulin sensitivity, carbohydrate and lipid metabolism in vitro and in vivo. Endocrine Abstracts, 0, , .	0.0	0
20	5[beta]-reductase (AKR1D1) is downregulated in patients with non-alcoholic fatty liver disease and protects against hepatocellular carcinoma cell proliferation in vitro. Endocrine Abstracts, 0, , .	0.0	0